ArticleThrombosis journal2026
Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCatheter-related thrombosis (CRT) poses significant risks for gynecologic cancer patients with central venous access devices. This retrospective cohort study evaluated the association between prophylactic rivaroxaban and catheter-related thrombosis in gynecologic oncology outpatients.
methodsThis single-center study at Fujian Maternity and Child Health Hospital (January 2021-June 2025) included 351 gynecologic oncology patients with peripherally inserted central catheters or implantable venous access ports. Primary exposure was rivaroxaban 10 mg daily for ≥ 30 days. Primary outcome was imaging-confirmed catheter-related thrombosis within 180 days. Inverse probability of treatment weighting (IPTW) was used to address confounding.
resultsAmong 351 patients (120 rivaroxaban, 231 controls), CRT occurred in 3 (2.5%) versus 42 (18.2%) patients, respectively (hazard ratio [HR] 0.12, 95% confidence interval [CI] 0.04-0.41; p < 0.001). The IPTW analysis confirmed this association (weighted HR 0.14, 95% CI 0.05-0.44). Major bleeding rates were 1.7% vs. 0.4% (HR 3.86, 95% CI 0.35-42.75; p = 0.273). Clinically relevant non-major bleeding occurred in 6.7% vs. 3.0% (HR 2.23, 95% CI 0.81-6.16; p = 0.121).
conclusionIn this retrospective cohort study, prophylactic rivaroxaban was associated with lower catheter-related thrombosis incidence in gynecologic cancer patients. These observational findings warrant prospective randomized validation. CLINICAL TRIAL NUMBER: Not applicable.
Identifiers
42919263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.